Gaëtane Rouvray

Gaëtane Rouvray has extensive work experience in the biopharmaceutical industry. Gaëtane is currently serving as the CMC Head & Chief Production Officer for Polyclonal Antibodies at XENOTHERA since November 2020. Prior to this, they worked at EFS - Atlantic Bio GMP as the CMC Project Manager & Qualified Person for Cell Therapy from September 2018 to October 2020.

Gaëtane also has a history with Sanofi, where they held various roles. From June 2017 to August 2018, they served as a CMC Project Manager for Monoclonal Antibodies. Before that, they were an Industrial Performance Manager at the Monoclonal Antibodies Manufacturing Site (Biolaunch) from December 2015 to May 2017. Gaëtane also worked as a Quality Assurance Manager for Tech Transfer & Process Validation for Monoclonal Antibodies from October 2013 to November 2015. Gaëtane initially joined Sanofi as part of the Graduate Program for Quality in Biologics, from September 2012 to September 2013.

Prior to their time with Sanofi, Gaëtane interned at Sanofi Pasteur as an Industrial Performance intern for Vaccines from August 2011 to February 2012. Gaëtane also interned at Sanofi as a Regulatory Affairs intern from January 2010 to June 2010.

Before transitioning into the biopharmaceutical industry, Gaëtane gained experience as an intern in Clinical Research at Servier from June 2009 to August 2009.

Gaëtane Rouvray received a Doctor of Pharmacy degree in the field of Pharmaceutical industry from Université de Rennes I, completing their studies from 2005 to 2012. In 2018, they obtained a PMP - Project Management Professional certification from the Institute of Project Management, focusing on Management de projet. Additionally, they earned an Engineer's degree in Biotechnology from ENSTBB Bordeaux INP, studying from 2010 to 2012.